Market Overview

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Share:
Related LGND
Ligand Announces Partner TG Therapeutics Shows Positive Pre-Clinical Data on IRAK4 Compounds
CRT Capital Initiates Ligand Pharmaceuticals With Buy
Related GSK
7 Trends Drug Investors Should Know
Top 4 Large-Cap Stocks In The Drug Manufacturers Industry With The Highest ROE
7 Top Dividend Sector Dogs Fetch 24% To 50% April Upsides (Seeking Alpha)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. PROMACTA in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.

Posted-In: News FDA

 

Related Articles (LGND + GSK)

Around the Web, We're Loving...